Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Mucosal Immunol. 2015 Feb 11;8(5):1083–1098. doi: 10.1038/mi.2014.135

Figure 3. Identification of Fms-related tyrosine kinase 3 ligand (FLT3L) responsive nasal DC subsets.

Figure 3

C57BL/6 wild type (WT) mice were implanted with 5–7x106 B16-FLT3 ligand melanoma cells (B16-FLT3L), or B16 melanoma cells (B16) and the nasal DC subsets were analyzed by multiparameter flow cytometry (a and b) or immunofluorescence (c) after ten to fourteen days of tumor implantation. (a) Representative flow cytometry panels comparing the expansion of putative nasal DCs in B16 or B16-FLT3L mice and (b) shows cumulative data from three individual experiments Error bars = SD. *=p<0.05, **=p<0.01, ns= not significant. (c) Nasal cryosections from mice implanted with B16-FLT3L or B16 melanoma cells were stained for CD3 (green), CD11c (red), and B220 (blue). Scale bars, 50μm. The entire NALT is depicted here by combining individual images in Adobe Photoshop CC.